

**Joshua R. Steinerman, M.D.**

Bala Cynwyd, Pennsylvania • jrsteinerman@gmail.com • (610) 724-3294

*Curriculum Vitae*, August 2023

**Pharmaceutical Industry Experience**

2018-  
present

**Jazz Pharmaceuticals**

Vice President, Neuropsychiatry

Formerly GW Pharmaceuticals (2019-2021), acquired by Jazz  
Executive Director, Clinical Development (2018-2019)

- Lead cross-functional development team for novel neurotherapeutics
- Led department of 15+ team members spanning Early Clinical Development, Clinical Pharmacology, Portfolio & Translational Strategy, Search & Evaluation
- Architect and execute Jazz CNS R&D growth strategy
- Provide strategic leadership for GW R&D, culminating in Jazz acquisition
- Spearhead development of new R&D capabilities
- Enterprise-wide framework for Real World Evidence
- Digital Health Working Group
- Interdisciplinary research strategy in Translational Neuroscience

2013-2018 **Teva Pharmaceuticals**

Therapeutic Area Head, Multiple Sclerosis and Headache

Senior Director, Global Clinical Development (2016-2018)

Director, Global Clinical Development (2013-2016)

- Lead and influence via cross-functional matrices and direct reports
- Execute clinical trials to ensure medical and scientific integrity
- Provide strategy and due diligence for business development activities
- Disseminate clinical data via publications and presentations
- Key achievements:
- Copaxone 40mg sNDA approval
- Phase 2, 3, 3b trials in Multiple Sclerosis
- Phase 3, 3b trials in Headache and Migraine
- Governance of portfolio of 8 CNS projects

2011-2013 **CRI Lifetree**  
Medical Director, Neurology

- Principal Investigator or Sub-Investigator on 50+ Phase 1-4 clinical trials in Alzheimer's disease, Multiple Sclerosis, Parkinson's disease, Schizophrenia, Depression, Bipolar, Pain, Smoking Cessation, Diabetes, hypertension, Infectious Disease, and other therapeutic indications
- Reported directly to the CEO of this growth-phase clinical trials company acquired by PRA Health Sciences

### **Entrepreneurial/Board Experience**

2012- Click Therapeutics, New York, New York

- Co-founded digital therapeutics company to develop, validate, and commercialize software as prescription medical treatments; consultant and board observer

2020- Board Director, Kohelet Yeshiva, Merion Station, Pennsylvania

2006-2014 Founder, ProGevity Neuroscience, acquired by Click Therapeutics

2011-2013 Clinical Advisory Board, Lexercise, Raleigh, North Carolina

### **Academic Experience and Postdoctoral Training:**

2008-2013 **Albert Einstein College of Medicine**, Bronx, New York  
Assistant Professor of Neurology (2008-2011)  
Clinical Assistant Professor of Neurology (2011-2013)

2006-2008 **Columbia University Medical Center**, New York, New York  
Clinical Research Fellow (Cognitive Neuropsychiatry)  
Neurological Institute and Psychiatric Institute

2003-2006 **Yale University School of Medicine**, New Haven, Connecticut  
Resident in Neurology

## **Education**

1998-2002 **State University of New York-Downstate Medical Center, Brooklyn**  
M.D. with commendation in investigative scholarship

1996-1998 **Columbia University**, New York, New York  
Postbaccalaureate Premedical Program

1992-1996 **Harvard University**, Cambridge, Massachusetts A.B., *Magna cum laude*

## **Board Certification, Medical Licensure, Clinical Appointments**

Board Certified in Neurology, American Board of Psychiatry and Neurology  
Board Certified in Behavioral Neurology and Neuropsychiatry, UCNS (inactive)  
Licensed in New York (241255), New Jersey (25MA08980500), Pennsylvania (MD443645)

2012-2013 Neurohospitalist, Virtua, Marlton, New Jersey  
2008-2011 Attending Neurologist, Montefiore Medical Center, Bronx, New York,  
2006-2011 Neurohospitalist, White Plains Hospital Center, White Plains, New York,  
2006-2008 Assistant Attending Neurologist, New York-Presbyterian, New York, New York,  
2002-2003 Intern in Medicine, Maimonides Medical Center, Brooklyn, New York,

## **Research Investigator Experience**

2013 Principal Investigator, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of XXXXX in Subjects with Mild to Moderate Alzheimer's Disease. Sponsor: TauRx

2012-2013 Principal Investigator, A Phase 1 Randomized Study of XXXXX in Subjects with Relapsing-Remitting Multiple Sclerosis. Sponsor: Medimmune

2012-2013 Principal Investigator, A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of XXXXX in Patients with Parkinson's Disease. Sponsor: AstraZeneca

2012-2013 Principal Investigator, A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXXX in Subjects with Prodromal or Mild Alzheimer's

Disease. Sponsor: Biogen

2012-2013 Principal Investigator, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Two Year Study to Evaluate the Effect of Subcutaneous XXXXX on Cognition and Function in Prodromal Alzheimer's Disease. Sponsor: Roche

2012-2013 Principal Investigator, A Phase 2, randomized, double-dummy, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of XXXXX for the treatment of symptoms of agitation in patients with Alzheimer's disease. Sponsor: Avanir

2011-2012 Principal Investigator, An Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetic Profile of XXXXX in Patients Diagnosed with Parkinson's Disease. Sponsor: Hisamitsu

2011-2013 Sub-Investigator, 50+ Phase I-IV clinical trials in Schizophrenia, Depression, Bipolar, Pain, Smoking Cessation, Binge Eating Disorder, Diabetes, Hypertension, Infectious Disease

2009-2011 Principal Investigator, Brain Aging Knowledge, Attitudes, and Beliefs in a Naturally Occurring Retirement Community, Center for Healthy Brain Aging

2009-2011 Principal Investigator, Focus Groups for Community Brain Health Research Design, Center for Healthy Brain Aging

2008-2011 Investigator, Einstein Aging Study, Albert Einstein College of Medicine

2009-2011 Co-investigator, Platform for Mental Fitness Efficacy Studies, Technology for Aging Gracefully Laboratory, University of Toronto

2008-2011 Co-investigator, Lifelogging Multimedia Technology Review for Memory-Impaired Elders, TAGlab, University of Toronto

2006-2009 Co-investigator, Training Control Processes in Cognitively-Healthy Older Adults, Division of Cognitive Neuroscience, Columbia University Medical Center

2008-2009 Principal Investigator, Safety and efficacy of positron emission tomography imaging with XXXXX. Sponsor: Bayer HealthCare

2006-2008 Sub-investigator, 13 clinical trials in Alzheimer's disease and Mild Cognitive Impairment, Columbia University Medical Center

2006-2008 Research neurologist, Washington Heights-Inwood Community Aging Project, Columbia University Medical Center, New York, NY

2006-2008 Research neurologist, Alzheimer's Disease Research Center, Columbia University Medical Center

2001 Research assistant, Laboratory of Patrick Hof, M.D., Department of Neuroscience, Mount Sinai Medical Center, New York, NY

1999 Research assistant, Laboratory of Robert Muller, Ph.D., Department of Physiology, SUNY-Downstate Medical Center, Brooklyn, NY

1998-1999 Research assistant, Laboratory of Illana Gozes, Ph.D., Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv, Israel

## Bibliography

### Original Articles

Nicholas J, Lublin F, Klineova S, Berwaerts J, Chinnapongse R, Checketts D, Javaid S, **Steinerman JR**. Nabiximols efficacy in people with MS with spasticity: treatment effects on spasticity Numeric Rating Scale, muscle spasm frequency, and spastic muscle tone in 2 randomized clinical trials. *Multiple Sclerosis and Related Disorders* 2023; 75:10475. (PMID: 37209500)

Cameron M, Bethoux F, Field-Fote E, Lenderking WR, Zaiser E, Cutts KN, Wagner JM, Berwaerts J, **Steinerman JR**. Development of an Integrated Conceptual Model of Multiple Sclerosis Spasticity. *Disability and Rehabilitation* 2023 (PMID: 37480330)

Salter A, Cutter G, Marrie RA, Nichol K, **Steinerman JR**, Smith KMJ, Fox RJ. Sources of Cannabis Information and Medical Guidance for Neurological Use: NARCOMS Survey of People Living with Multiple Sclerosis. *Neurology Clinical Practice* 2022; 12(2):102-112. (PMID: 35733947)

Salter A, Fox RJ, Cutter G, Marrie RA, Nichol KE, **Steinerman JR**, Smith KMJ. A Survey of Cannabis Use in a Large US-Based Cohort of People Living With Multiple Sclerosis. *International Journal of MS Care* 2021; 23(6):245-252. (PMID: 35035295)

Comi G, Dadon Y, Sasson N, **Steinerman JR**, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick

S, Halevy N, Filippi M. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. *Multiple Sclerosis* 2021 (PMID: 34378456)

Videnovic A, Amara A, Comella C, Schweitzer P, Emsellem H, Liu K, Sterkel AL, Gottwald MD, **Steinerman JR**, Jochelson P, Zomorodi K, Hauser RA. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. *Movement Disorders* 2021; 36:2408-2412. (PMID: 34191352)

Giovannoni G, Knappertz V, **Steinerman JR**, Tansy AP, Li T, Krieger S, Uccelli A, Uitdehaag BMJ, Montalban X, Hartung HP, Sormani MP, Cree BAC, Lublin F, Barkhof F. A randomized, placebo-controlled phase 2 trial of laquinimod in primary progressive multiple sclerosis. *Neurology* 2020. (PMID: 32651286)

Bovis F, Carmisciano L, Signori A, Pardini M, **Steinerman JR**, Li T, Tansy AP, Sormani MP. Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data. *BMC Med* 2019;17(1):113. (PMID: 31208412)

Bovis F, De Stefano N, **Steinerman JR**, Knappertz V, Sormani MP. Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS. *Multiple Sclerosis* 2019; 25(2):217-223. (PMID: 29154721)

Bovis F, Signori A, Carmisciano L, Maietta I, **Steinerman JR**, Li T, Tansy AP, Sormani MP. Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas. *Annals of Neurology* 2018; 84(4): 621-625. (PMID: 30179270)

Koch MW, Cutter GR, Giovannoni G, Uitdehaag BMJ, Wolinsky JS, Davis MD, **Steinerman JR**, Knappertz V. Comparative utility of disability progression measures in PPMS. Analysis of the PROMiSe data set. *Neurology Neuroimmunology Neuroinflammation* 2017;4(4):e358. (PMID: 28680915)

Davis MD, Ashtamker N, **Steinerman JR**, Knappertz V. Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. *Neurology Neuroimmunology Neuroinflammation* 2017; 4(2): e327.

Iacoviello BM, **Steinerman JR**, Klein DB, Silver TL, Berger AG, Luo SX, Schork NJ. Clickotine, A Personalized Smartphone App for Smoking Cessation: Initial Evaluation *JMIR Mhealth Uhealth* 2017; 5(4):e56.

Zivadinov R, Dwyer MG, Ramasamy DP, Davis MD, **Steinerman JR**, Khan O. The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. *Journal of Neuroimaging* 2015; 25(6):989-95.

Wolinsky JS, Borresen TE, Dietrich DW, Wynn DR, Sidi Y, **Steinerman JR**, Knappertz V, Kolodny S, on behalf of the GLACIER Study Group. GLACIER: an open-label, randomized,

multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg/mL three-times weekly versus 20 mg/mL daily in patients with relapsing-remitting multiple sclerosis. *Multiple Sclerosis & Related Disorders* 2015;4(4):370–376.

Zivadinov R, Dwyer M, Barkay H, **Steinerman JR**, Knappertz V, Khan O. Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1- hypointense "black holes": a post hoc magnetic resonance imaging analysis. *Journal of Neurology* 2015; 262(3):648-53.

White R, Lipton RB, Hall CH, **Steinerman JR**. Non-melanoma Skin Cancer is Associated with Reduced Alzheimer's Risk. *Neurology* 2013,80(21):1966-72.

**Steinerman JR**, Lipton RB, Rapkin BD, Quaranto BR, Schwartz CR. Factors associated with openness to research participation in an aging community: The importance of technophilia and social cohesion. *Gerontechnology* 2013, 11(4): 504-512.

Crete-Nishihata M, Baecker RM, Massimi M, Ptak D, Campigotto R, Kaufman L, Brickman AM, Turner G, **Steinerman JR**, Black SE. Reconstructing the past: personal memory technologies are not just personal and not just for memory. *Human-Computer Interaction* 2012, 27:92-123.

**Steinerman JR**. Minding the Aging Brain: Technology-Enabled Cognitive Training for Healthy Elders. *Current Neurology and Neuroscience Reports* 2010, 10(5):374-380.

Blumen HB, Gopher D, **Steinerman JR**, Stern Y. Training Cognitive Control in Older Adults with the Space Fortress Game: The Role of Training Instructions and Basic Motor Ability. *Frontiers in Aging Neuroscience* 2010, 2:145.

**Steinerman JR**, Sliwinski MJ, Hall CB, Lipton RB. Modeling Cognitive Trajectories Within Longitudinal Studies: A Focus on Elders. *Journal of the American Geriatrics Society* 2010, 58:S313-318.

**Steinerman JR**, Irizarry M, Scarmeas N, Raju S, Brandt J, Albert M, Blacker D, Hyman B, Stern Y. Distinct Pools of  $\beta$ -amyloid in Alzheimer Disease-Affected Brain: A Clinical-Pathological Study. *Archives of Neurology* 2008, 65(7): 906-912.

**Steinerman JR**, Honig LS. Laboratory Biomarkers in Alzheimer's Disease. *Current Neurology and Neuroscience Reports* 2007, 7:381-387.

## Book Chapters

**Steinerman JR**, Lipton RB. “Alzheimer’s Disease,” in S.K. Whitbourne and Sliwinski, M.J. (eds.) *The Wiley-Blackwell Handbook of Adulthood and Aging*, First edition (United Kingdom: Blackwell, 2012) 293-311.

**Steinerman JR**, Marder KS. “Lewy Body Dementias,” in L.P. Rowland and Pedley, T.A. (eds.) *Merritt’s Neurology 12<sup>th</sup> edition* (Philadelphia: Lippincott, 2010) 721-722.

**Steinerman JR**, Noe E, Stern Y. “Cognitive Aspects of Parkinson’s Disease and Other Neurodegenerative Movement Disorders,” in J.I. Sirven and Malamut, B.L. (eds.) *Clinical Neurology of the Older Adult* (Philadelphia: Lippincott, 2008) 376-392.

### **Grant Support**

2010-2011 Einstein-Montefiore Institute for Clinical and Translational Research Career Development Award, NIH grants KL2RR025749, UL1RR025750

2006-2011 NIH Clinical Research Loan Repayment Program

2009-2010 Brain Aging Knowledge, Attitudes, and Beliefs in an Urban Naturally-Occurring Retirement Community, Resnick Gerontology Center Pilot Grant

2006-2008 National Research Service Award NIH/NIMH training grant 5T32MH020004

### **Committee Memberships**

2010-2017 Data Safety Monitoring Board, “Exercise, Aging, and Cognition: Effects and Mechanisms” PI: Yaakov Stern, PhD

2010-2011 Technology Interest Area, International Society to Advance Alzheimer’s Research and Treatment (ISTAART), Alzheimer’s Association

2009-2010 Health Inequities Think Tank, Division of Community Collaboration and Implementation Science, Albert Einstein College of Medicine

### **Awards**

2010 Louis and Gertrude Feil Faculty Scholar in Neurology, Office of the Dean, Albert Einstein College of Medicine

2010 Men's Division Research Scholar, Albert Einstein College of Medicine

2009 Travel Fellowship Award, International Conference on Alzheimer's Disease, Vienna, Austria

2007 Travel Fellowship Award, American Neurological Association, 132<sup>nd</sup> Annual Meeting, Washington, D.C.

2006 Resident of the Year (Teaching Excellence), Department of Neurology, Yale School of Medicine

2002 Commendation in Investigative Scholarship, Downstate College of Medicine

2001 Medical Student Geriatric Scholar, American Federation for Aging Research

1996 *Magna Cum Laude*, Harvard College

1993-1995 John Harvard Scholarship for Academic Achievement

1992 Valedictorian, Lawrence High School, Cedarhurst, NY

### **Languages**

Proficient in Spanish, Hebrew, Yiddish